Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.51 |
| ▸ | SRC | P12931 | 9/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | BCR | P11274 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14421398 | 1.00 | CYP2D6 (0.56) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL5025184 | 0.89 | SRC (0.50) | CYP2D6CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL17921471 | 0.89 | CYP1A2 (0.58) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL27958219 | 0.89 | CYP2D6 (0.66) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL5139995 | 0.84 | SRC (0.46) | CYP2D6KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL6508978 | 0.82 | ALDH1A1 (0.57) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL4317372 | 0.82 | ALDH1A1 (0.57) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL21199087 | 0.82 | CYP2D6 (0.54) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL30946649 | 0.82 | CYP2D6 (0.54) | CYP2D6CYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL2163402 | 0.81 | MAP2K1 (0.55) | CYP2D6MAP2K1SRCTSHRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023098592-A1 | PREPARATION METHOD FOR CARBON-LOADED IRON-BASED CATALYST AND USE THEREOF IN SYNTHESIS OF INTERMEDIATES OF ANTI-CANCER INHIBITORS | 奥锐特药业股份有限公司 | 2023-06-08 | — | — | WO | claimed |
| CN-114315595-A | Preparation method of carbon-supported iron-based catalyst and synthesis application of anti-cancer inhibitor intermediate thereof | 湖南大学 | 2022-04-12 | — | — | CN | claimed |
| US-7705145-B2 | Process for the preparation of 4-(3′-chloro-4′-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2010-04-27 | — | — | US | claimed |
| EP-1546119-B1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | claimed |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | claimed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | claimed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | claimed |
| CN-120703269-A | Method for determining positional isomer of 4-methoxy-5- (3-morpholinopropoxy) -2-nitrobenzonitrile | 山东鲁抗医药股份有限公司 | 2025-09-26 | — | — | CN | disclosed |
| CN-120703269-A | Method for determining positional isomer of 4-methoxy-5- (3-morpholinopropoxy) -2-nitrobenzonitrile | 山东鲁抗医药股份有限公司 | 2025-09-26 | — | — | CN | disclosed |
| CN-114315595-B | Preparation method of carbon-supported iron-based catalyst and application of intermediate synthesis of anticancer inhibitor of carbon-supported iron-based catalyst | 奥锐特药业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023098592-A1 | PREPARATION METHOD FOR CARBON-LOADED IRON-BASED CATALYST AND USE THEREOF IN SYNTHESIS OF INTERMEDIATES OF ANTI-CANCER INHIBITORS | 奥锐特药业股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-1681796-A | Process for preparing 4- (3 '-chloro-4' -fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005068433-A9 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005070909-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GEFITINIB | NATCO PHARMA LIMITED (IN) | 2005-08-04 | — | — | WO | disclosed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | CYP3A7, CYP3A5, CYP4B1 | CYP2D6 16/4885CYP1A2 14/4885CYP2C19 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.